December 22, 2025- Thermo Fisher Scientific Inc. announced the enrollment of the first patient in the new PPD™ CorEvitas™ Alzheimer’s Disease Registry. Designed as an international, multi-country initiative, the registry will generate robust, harmonized, fit-for-purpose real-world data under a common global protocol to support novel evaluations of drug safety and effectiveness that are critical for regulator, clinician, patient and caregiver communities.
Its longitudinal design, coupled with clinician-reported data from routine practice, will generate a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry will illuminate long-term safety, treatment patterns and the evolving use of approved therapies, while also helping to identify unmet medical needs, clarify the disease’s impact on patients, and evaluate the clinical outcomes associated with existing treatment options.